补益心脾对产后抑郁症大鼠模型Th1/Th2平衡细胞免疫调节作用的影响

目的:观察产后抑郁症大鼠模型Th1和Th2细胞比例的变化并探讨参芪解郁方对产后抑郁症Th1/Th2平衡的调节作用机制。方法:选取SD雌性大鼠90只,随机分为正常组、模型组、假手术组、中药组、西药组,每组6只,设灌胃1、2、4周3个时间点。采用流式细胞术检测3个时间点各组大鼠外周血Th1细胞和Th2细胞比例,并计算Th1/Th2比值。结果:1周模型组Th1及Th2细胞比例较正常组降低,差异有统计学意义(P 0. 05),2周、4周模型组较正常组升高,差异有统计学意义(P 0. 05); 1周模型组Th1/Th2比值较正常组升高,差异有统计学意义(P 0. 05),2周、4周模型组较正常组降低,差异有统计学意义(P 0. 05) 3、1周中药组Th1细胞比例较模型组升高,2周、4周中药组较模型组降低,差异有统计学意义(P 0. 05)。1周中药组Th2细胞比例较模型组升高(P 0. 05); 2周、4周中药组较模型组降低,差异有统计学意义(P 0. 05)。1周中药组Th1/Th2比值较模型组降低; 2周中药组较模型升高(P 0. 05),4周中药组升高明显,差异有统计学意义(P 0. 05)。结论:Th1/Th2平衡细胞参与产后抑郁症大鼠模型的发生发展,参芪解郁方通过对产后抑郁症Th1/Th2失衡状态的调节而发挥其效用。     

母婴分离产后抑郁大鼠脑内5-羟色胺及其代谢产物的变化及参芪解郁方的干预作用

目的：观察母婴分离产后抑郁大鼠前额叶皮质和海马5-羟色胺（5-HT）及其代谢产物5-羟吲哚乙酸（5-HIAA）的含量,探讨不同剂量参芪解郁方的干预作用。方法：60只SD孕鼠,随机分为正常组、模型组、中药高剂量组、中药中剂量组、中药低剂量组和西药组,采用母婴分离法制备产后抑郁大鼠,灌胃两周后检测各组大鼠前额叶皮质、海马5-HT及其代谢产物5-HIAA含量。结果：模型组强迫游泳不动时间较正常组显著增加（P<0.01）,蔗糖水消耗量、旷场实验水平得分和垂直得分均较正常组显著降低（P<0.01）。中药高、中、低剂量组和西药组强迫游泳不动时间较模型组显著降低（P<0.01）;中药高、中、低剂量组和西药组蔗糖水消耗量、旷场实验水平得分较模型组均显著升高（P<0.01,P<0.05）;中药高、中剂量组和西药组旷场实验垂直得分较模型组均显著升高（P<0.01）。模型组前额叶皮质、海马5-HT及其代谢产物5-HIAA含量较正常组均显著降低（P<0.01）。中药高、中、低剂量组和西药组前额叶皮质、海马5-HT及其代谢产物5-HIAA含量较模型组均升高（P<0...     

出血性中风病机再认识

出血性中风在发病前既已形成瘀血阻滞、脉道不利的病理基础,并贯穿疾病全程。自脑脉破裂、血溢脉外后,出现瘀停脉外、神机失用,内风旋动、风火相煽,血行不畅、痰水形成,诸邪化毒、损伤脑髓等一系列急性期病机变化。恢复期和后遗症期则以精亏髓减、正虚邪藏为病机,不及时医治则有痴呆及复中风风险。     

多模态神经影像学在焦虑抑郁共病连接组学研究中的应用

正焦虑抑郁共病逐渐受到精神病学研究者的关注,二者共性的发病机制是目前研究的热点。异常的神经环路及连接方式可能是精神疾病的重要发病机制之一,而焦虑与抑郁则可能具有共性的神经环路,这种共性的机制可能与两者共性的肝郁病机具有相关性。多模态神经影像学是目前神经影像研究领域的尖端技术,可能在连接组学的研究方面提供重要支撑,有希望在焦虑抑郁共病     

醒脑静注射液治疗急性期脑出血一例报告

高血压性脑出血急性期病情危重,及时有效地抢救和治疗是降低病死率、减轻病残程度、提高患者生活质量的关键。大量对照试验显示,外科治疗并无明显优势,而内科仍着眼于对症处理,治疗并发症,等待其自然康复,而中医药在治疗出血性中风方面积累了丰富的经验。在西医脑出血治疗指南基础上,针对脑出血淤血贯穿疾病始终,风痰瘀热并存的病机。我     

Activating Blood Circulation to Remove Stasis Treatment of Hypertensive Intracerebral Hemorrhage: A Multi-Center Prospective Randomized Open-Label Blinded-Endpoint Trial

Objective:To investigate the efficacy and safety of the Chinese herbal therapeutic regimen of activating blood circulation(TRABC) in treatment of hypertensive intracerebral hemorrhage(HICH).Methods:This was a multi-center prospective randomized open-label blinded-endpoint(PROBE) trial with HICH admitted to 12 hospitals.Totally 240 participants were randomized to the treatment group treated with TRABC in addition to conventional Western treatment or the control group with conventional Western treatment equally for 3 months.Primary outcome was degree of disability as measured by modified Rankin Scale(mRS).Secondary outcomes were the absorption of hematoma and edema,National Institutes of Health Stroke Scale(NIHSS) scores and patient-reported outcome measures for stroke and Barthel activities of daily living index.Adverse events and mortality were also recorded.Results:After 3 months of treatment,the rate of mRS 0-1 and mRS 0-2 in the treatment group was 72.5%and 80.4%,respectively,and in the control group 48.1%and 63.9%,respectively,with a significant difference between groups(P0.01).Hematoma volume decreased significantly at day 7 of treatment in the treatment group than the control group(P=0.038).Average Barthel scores in the treatment group after treatment was 89.11 ± 19.93,and in the control group 82.18 ±24.02(P=0.003).NIHSS scores of the two groups after treatment decreased significantly compared with before treatment(P=0.001).Patient-reported outcomes in the treatment group were lower than the control group at day 21 and 3 months of treatment(P0.05).There were 4 deaths,2 in each group,and 11 adverse events,6 in the treatment group and 5 in the control group.Conclusion:The integrative therapy combined TRABC with conventional Western treatment for HICH could promote hematoma absorption thus minimize neurologic impairment,without increasing intracerebral hematoma expansion and re-bleeding.